Biologic Drug R&D in China - Current State and Future Development 5/1/2013 \| published by: JZMed, Inc. ... biological medicines. In the recent several years growing numbers of Chinese pharma and biopharma companies have been steadily increasing their investment in innovative drug R&D, including the discovery and development of novel biologics. The current ... \| read more...	$3,685.00
Personalized Medicine Market Analysis 5/1/2013 \| published by: RNCOS ... per individuals. The growing research applications and identification of molecular markers towards disease predisposition and progression have led to the growth of personalized medicine. Industry players have also rapidly adopted this field and are progressing ... \| read more...	$1,200.00
Genetic Testing Market Outlook to 2017 5/1/2013 \| published by: RNCOS ... 140-page report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to ... \| read more...	$1,200.00
US Personalized Cancer Genome Sequencing Marketrncos 5/1/2013 \| published by: RNCOS ... the most attractive sectors due to its inherent capability of high revenue generation and efficiency in terms of personalized treatment. In order to properly analyze the virtues and significance of the US personalized cancer Whole-Genome ... \| read more...	$1,200.00
Novartis AG – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Novartis AG’s corporate ... \| read more...	$1,500.00
Generex Biotechnology Corporation – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ... \| read more...	$1,500.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - EU Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and ... \| read more...	$4,450.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme and myoglobin. Furthermore, ... \| read more...	$4,450.00
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry 4/30/2013 \| published by: GlobalData ... the Pharmaceutical Industry report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 ... \| read more...	$2,995.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players 4/30/2013 \| published by: GlobalData ... of the major killers in the mature markets. Though the incidence of ACS is either in decline or steady across the US and European countries, millions of ACS and suspected ACS patients still visit emergency ... \| read more...	$3,500.00
Nektar Therapeutics – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Nektar Therapeutics’s corporate ... \| read more...	$1,500.00
Elan Corporation, plc – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ... \| read more...	$1,500.00
Antisense Therapeutics Limited – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ... \| read more...	$1,500.00
Genentech, Inc. – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Genentech, Inc.’s corporate ... \| read more...	$1,500.00
Celgene Corporation – Product Pipeline Review – 2013 4/30/2013 \| published by: Global Markets Direct ... includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Celgene Corporation’s corporate ... \| read more...	$1,500.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - US Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... this market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme ... \| read more...	$4,450.00
MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - South America Analysis and Market Forecasts 4/30/2013 \| published by: GlobalData ... diagnostics market remains of high interest due to advancements in assay sensitivity both on laboratory and point-of-care platforms. GlobalData expects these advancements to have an impact on other diagnostic tests such as creatine kinase-MB isoenzyme ... \| read more...	$4,450.00
ImmunoGen, Inc - SWOT, Strategy and Corporate Finance Report 4/26/2013 \| published by: MarketLine ... actions, providing a 360° view of the company. Features: Detailed information on ImmunoGen, Inc required for business and competitor intelligence needs A study of the major internal and external factors affecting ImmunoGen, Inc in the ... \| read more...	$175.00
Biotechnology in the US - Industry Risk Rating Report 4/24/2013 \| published by: IBISWorld ... the business operating environment'. The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry itself (structural risk), ... \| read more...	$1,020.00
Cell Culture: The Market for Media, Sera and Reagents, 5th Edition 4/24/2013 \| published by: Kalorama Information ... for more than 50 years; however, cell culture techniques have been applied to production systems for only about 26 years. The cell culture industry, which began in the late 1980s from the utilization of recombinant ... \| read more...	$3,995.00
Analytical Tool - Cancer Therapeutic Antibodies 4/22/2013 \| published by: BioSeeker Group AB ... same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of ... \| read more...	$14,808.75
Antibodies in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... for the second wave in the lucrative field of therapeutic antibodies. There are today 303 companies plus partners developing 598 antibody drugs in 1408 developmental projects in cancer. In addition, there are 6 suspended drugs ... \| read more...	$5,621.25
Biologicals in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developing 1460 biological drugs in 3194 developmental projects in cancer. In addition, there are 25 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 868 drugs. Biologicals In ... \| read more...	$9,371.25
Cancer Stem Cells Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today ... \| read more...	$5,621.25
Gene Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 95 drugs. Gene Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ... \| read more...	$5,621.25

< prev 1 2 3 4 5 6 7 8 9 10 next >